CLDX PE Ratio & Valuation,Is CLDX Overvalued

CLDX Relative Valuation

CLDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLDX is overvalued; if below, it's undervalued.

Historical Valuation

Celldex Therapeutics Inc (CLDX) is now in the Fair zone, suggesting that its current forward PS ratio of 509.37 is considered Fairly compared with the five-year average of -13.33. The fair price of Celldex Therapeutics Inc (CLDX) is between 18.86 to 42.57 according to relative valuation methord.

Relative Value

Fair Zone

18.86-42.57

Current Price：27.13

Fair

-6.15

-4.66

EV/EBITDA

Celldex Therapeutics Inc. (CLDX) has a current EV/EBITDA of -4.66. The 5-year average EV/EBITDA is -2.36. The thresholds are as follows: Strongly Undervalued below -9.68, Undervalued between -9.68 and -6.02, Fairly Valued between 1.29 and -6.02, Overvalued between 1.29 and 4.95, and Strongly Overvalued above 4.95. The current Forward EV/EBITDA of -4.66 falls within the Historic Trend Line -Fairly Valued range.

-4.08

EV/EBIT

Celldex Therapeutics Inc. (CLDX) has a current EV/EBIT of -4.08. The 5-year average EV/EBIT is -9.76. The thresholds are as follows: Strongly Undervalued below -21.81, Undervalued between -21.81 and -15.79, Fairly Valued between -3.73 and -15.79, Overvalued between -3.73 and 2.30, and Strongly Overvalued above 2.30. The current Forward EV/EBIT of -4.08 falls within the Historic Trend Line -Fairly Valued range.

509.37

Celldex Therapeutics Inc. (CLDX) has a current PS of 509.37. The 5-year average PS is 570.15. The thresholds are as follows: Strongly Undervalued below 13.79, Undervalued between 13.79 and 291.97, Fairly Valued between 848.33 and 291.97, Overvalued between 848.33 and 1126.51, and Strongly Overvalued above 1126.51. The current Forward PS of 509.37 falls within the Historic Trend Line -Fairly Valued range.

-6.98

P/OCF

Celldex Therapeutics Inc. (CLDX) has a current P/OCF of -6.98. The 5-year average P/OCF is -11.67. The thresholds are as follows: Strongly Undervalued below -30.98, Undervalued between -30.98 and -21.33, Fairly Valued between -2.01 and -21.33, Overvalued between -2.01 and 7.64, and Strongly Overvalued above 7.64. The current Forward P/OCF of -6.98 falls within the Historic Trend Line -Fairly Valued range.

-7.93

P/FCF

Celldex Therapeutics Inc. (CLDX) has a current P/FCF of -7.93. The 5-year average P/FCF is -14.67. The thresholds are as follows: Strongly Undervalued below -30.34, Undervalued between -30.34 and -22.51, Fairly Valued between -6.83 and -22.51, Overvalued between -6.83 and 1.01, and Strongly Overvalued above 1.01. The current Forward P/FCF of -7.93 falls within the Historic Trend Line -Fairly Valued range.

Celldex Therapeutics Inc (CLDX) has a current Price-to-Book (P/B) ratio of 3.06. Compared to its 3-year average P/B ratio of 3.82 , the current P/B ratio is approximately -19.94% higher. Relative to its 5-year average P/B ratio of 4.30, the current P/B ratio is about -28.99% higher. Celldex Therapeutics Inc (CLDX) has a Forward Free Cash Flow (FCF) yield of approximately -9.94%. Compared to its 3-year average FCF yield of -7.89%, the current FCF yield is approximately 26.03% lower. Relative to its 5-year average FCF yield of -6.49% , the current FCF yield is about 53.11% lower.

3.01

P/B

Median3y

3.82

Median5y

4.30

-9.94

FCF Yield

Median3y

-7.89

Median5y

-6.49

Competitors Valuation Multiple

The average P/S ratio for CLDX's competitors is , providing a benchmark for relative valuation. Celldex Therapeutics Inc Corp (CLDX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CLDX increased by 7.20% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.32K to -12.46K.

The secondary factor is the Revenue Growth, contributed -100.00%to the performance.

Overall, the performance of CLDX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-100.00%

3.19M → 0.00

Revenue Growth

844.00%

-1.32K → -12.46K

Margin Expansion

-736.80%

1.26 → -8.01

P/E Change

7.20%

25.27 → 27.09

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Celldex Therapeutics Inc (CLDX) currently overvalued or undervalued?

What is Celldex Therapeutics Inc (CLDX) fair value?

CLDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Celldex Therapeutics Inc (CLDX) is between 18.86 to 42.57 according to relative valuation methord.

How does CLDX's valuation metrics compare to the industry average?

What is the current P/B ratio for Celldex Therapeutics Inc (CLDX) as of Dec 16 2025?

As of Dec 16 2025, Celldex Therapeutics Inc (CLDX) has a P/B ratio of 3.06. This indicates that the market values CLDX at 3.06 times its book value.

What is the current FCF Yield for Celldex Therapeutics Inc (CLDX) as of Dec 16 2025?

As of Dec 16 2025, Celldex Therapeutics Inc (CLDX) has a FCF Yield of -9.94%. This means that for every dollar of Celldex Therapeutics Inc’s market capitalization, the company generates -9.94 cents in free cash flow.

What is the current Forward P/E ratio for Celldex Therapeutics Inc (CLDX) as of Dec 16 2025?

As of Dec 16 2025, Celldex Therapeutics Inc (CLDX) has a Forward P/E ratio of -6.25. This means the market is willing to pay $-6.25 for every dollar of Celldex Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Celldex Therapeutics Inc (CLDX) as of Dec 16 2025?

As of Dec 16 2025, Celldex Therapeutics Inc (CLDX) has a Forward P/S ratio of 509.37. This means the market is valuing CLDX at $509.37 for every dollar of expected revenue over the next 12 months.

CLDX Valuation